Neumotropio Inhalation (Dry Powder)
Tiotropium
10mcg
PHARMALINE S.A.L
| Pack size | 30 Hard Capsules (2 HDPE Bottles of 15 Capsules) + 1 Zephir Inhaler |
|---|---|
| Dispensing mode | POM |
| Source | LEBANON |
| Agent | CITY MEDICAL STORE |
| Retail Price | 153.50 AED |
Indications
Neumotropio Inhalation (Dry Powder) is used for:
Tiotropium is indicated for the long term once daily maintenance treatment of bronchospasm and dyspnoea associated with, chronic obstructive pulmonary disease (COPD), including, chronic bronchitis and emphysema.
Adult Dose
Inhalation
Chronic obstructive pulmonary disease
Adult: As Inhaler: 2 puffs (18mcg) once daily.
As inhalation cap: 1 cap (18 mcg) daily via inhaler device, at the same time each day.
Child Dose
Inhalation
Chronic obstructive pulmonary disease
Child> 12 years: As Inhaler: 2 puffs (18mcg) once daily.
Child> 18 years: As inhalation cap: 1 cap (18 mcg) daily via inhaler device, at the same time each day.
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<50 Use w/ caution.
Administration
Contra Indications
Hypersensitivity to atropine and its derivatives (e.g. ipratropium).
Precautions
Not intended for use as initial treatment for acute bronchospasm and as monotherapy for asthma. Patient w/ narrow-angle glaucoma, prostatic hyperplasia/bladder neck obstruction, cystic fibrosis. History of MI (<6 mth), or unstable or life threatening cardiac arrhythmia w/in the past yr. Moderate to severe renal impairment (CrCl ≤50 mL/min). Pregnancy and lactation. Patient Counselling This drug may cause dizziness and blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor pulmonary function.
Pregnancy-Lactation
Pregnancy
The limited human data with therapy during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes
Poorly or moderately controlled asthma in pregnancy increases maternal risk of preeclampsia and infant prematurity, low birth weight, and small for gestational age; level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control
Lactation
There are no data on presence of tiotropium in human milk, effects on breastfed infant, or effects on milk production; tiotropium is present in milk of lactating rats; however, clinical relevance of these data are not clear. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition
Interactions
Other anticholinergic agents.
Adverse Effects
Side effects of Tiotropium :
>10%
Upper respiratory tract infection (41%), Dry mouth (16%), Sinusitis (11%)
1-10%
Abdominal pain, Allergic reaction, Angina pectoris (including aggravated angina pectoris), Cataract, Chest pain (nonspecific), Constipation, Depression, Dyspepsia, Dysphonia, Edema, Epistaxis, Gastroesophageal reflux, Herpes zoster, Hypercholesterolemia, Hyperglycemia, Infection, Laryngitis, Leg pain, Moniliasis, Myalgia, Paresthesia, Pharyngitis, Rash, Rhinitis, Skeletal pain, Stomatitis (including ulcerative stomatitis), Urinary tract infection, Vomiting
<1%
Angioedema, Fibrillation, Supraventricular tachycardia, Urinary retention
Mechanism of Action
Tiotropium bromide, a long-acting quaternary ammonium antimuscarinic, is structurally related to ipratropium. It is a nonselective competitive antagonist of muscarinic (M1-M5) receptors and causes bronchodilation by inhibiting the actions of acetylcholine and other cholinergic stimuli at M3 receptors in the smooth muscle of the respiratory tract.
Note
Neumotropio 10mcg Inhalation (Dry Powder) manufactured by PHARMALINE S.A.L . Its generic name is Tiotropium. Neumotropio is availble in United Arab Emirates.
Farmaco UAE drug index information on Neumotropio Inhalation (Dry Powder) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.